UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey results from 9amHealth reveal that access to these medications has become a ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

RAs, and DPP-4is may offer benefits for patients with COPD, but clinical evidence comparing their effectiveness in reducing ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

Spend billions of dollars to cover anti-obesity drugs under Medicare and Medicaid, or deny more than 7 million people access ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...